SUBSTITUIERTE XANTHINDERIVATE

European patent · EP2265612 · In force

Register entry

Publication number
EP2265612
Application number
EP09715566
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Feb 27, 2009
Published
Dec 29, 2010
Granted
Apr 5, 2017
Protection ends at the latest
Feb 26, 2029
Next annual fee due
Feb 28, 2027
IPC classes
C07D 473/06 (2006.01)
A61K 31/522 (2006.01)
A61P 1/16 (2006.01)
A61P 13/12 (2006.01)
Priority
US 67736 P 29.02.2008
US 134568 P 11.07.2008
US 198715 P 07.11.2008
PCT application
PCT/US2009/001294 27.02.2009
PCT publication
WO2009/108375 03.09.2009
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Mar 1, 2026

    Change

    Published in Swissreg on 01.03.2026

  2. Mar 4, 2025

    Change

    Published in Swissreg on 04.03.2025

  3. Mar 1, 2024

    Change

    Published in Swissreg on 01.03.2024

  4. Mar 6, 2023

    Change

    Published in Swissreg on 06.03.2023

  5. Apr 5, 2017

    Granted

    Published in Swissreg on 05.04.2017

Parties

Holder

Concert Pharmaceuticals, Inc.

CONCERT PHARMACEUTICALS, INC.

99 Hayden Avenue, Suite 500, Lexington, MA 02421, US

Inventor

TUNG, Roger, D.

Lexington MA 02420, US

LIU, Julie, F.

Lexington MA 02420, US

HARBESON, Scott, L.

Cambridge MA 02140, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.